Abstract
Fitusiran was FDA approved on March 28, 2025, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies). This article contains an overview of hemophilia and current treatment and prophylactic strategies, highlighting the key differences between fitusiran and other agents used for prophylaxis. It summarizes antithrombin’s role in the coagulation cascade and how fitusiran uses a novel mechanism as a small interfering RNA inhibitor that reduces expression of antithrombin. Pivotal clinical trials that led to its FDA approval are discussed, including dosing regimens, therapeutic drug monitoring, adverse effects, and clinical outcomes. This article provides in-depth information and clinical critique inclusive of and beyond the package insert guidance for advanced practitioners in hematology/oncology.
References
Badulescu, O. V., Badescu, M. C., Bojan, I. B., Vladeanu, M., Filip, N., Dobreanu, S., Tudor, R., Ciuntu, B. M., Tanevski, A., & Ciocoiu, M. (2024). Thrombotic disease in hemophilic patients: Is this a paradox in a state of hypocoagulability? Diagnostics (Basel, Switzerland), 14(3), 286. https://doi.org/10.3390/diagnostics14030286
Centers for Disease Control and Prevention. (2024). Hemophilia. https://www.cdc.gov/hemophilia/index.html
Genentech, Inc. (2025). Emicizumab-kxwh (Hemlibra) package insert. https://www.gene.com/download/pdf/hemlibra_prescribing.pdf
Kenet, G., Nolan, B., Zulfikar, B., Antmen, B., Kampmann, P., Matsushita, T., You, C. W., Vilchevska, K., Bagot, C. N., Sharif, A., Peyvandi, F., Young, G., Negrier, C., Chi, J., Kittner, B., Sussebach, C., Shammas, F., Mei, B., Andersson, S., & Kavakli, K. (2024). Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: The ATLAS-PPX trial. Blood, 143(22), 2256–2269. https://doi.org/10.1182/blood.2023021864
Kruse-Jarres, R., Peyvandi, F., Oldenburg, J., Chang, T., Chebon, S., Doral, M. Y., Croteau, S. E., Lambert, T., Kempton, C. L., Pipe, S. W., Ko, R. H., Trzaskoma, B., Dhalluin, C., Bienz, N. S., Niggli, M., Lehle, M., Paz-Priel, I., Young, G., & Jiménez-Yuste, V. (2022). Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: Experience from the HAVEN 1-4 studies. Blood Advances, 6(24), 6140–6150. https://doi.org/10.1182/bloodadvances.2022007458
Ljung, R., Auerswald, G., Benson, G., Dolan, G., Duffy, A., Hermans, C., Jiménez-Yuste, V., Lambert, T., Morfini, M., Zupančić-Šalek, S., & Santagostino, E. (2019). Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. European Journal of Haematology, 102(2), 111–122. https://doi.org/10.1111/ejh.13193
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A.,…Evatt, B. L. (2007). Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. The New England Journal of Medicine, 357(6), 535–544. https://doi.org/10.1056/NEJMoa067659
Matino, D., Palladino, A., Taylor, C. T., Hwang, E., Raje, S., Nayak, S., McDonald, R., Acharya, S. S., Mahlangu, J., Jiménez-Yuste, V., Choraria, N., Yang, R., Li, C. K., Al-Khabori, M., Wali, Y., Morales Adrián, J., Park, Y. S., Zülfikar, O. B., & Teeter, J. (2025). Marstacimab prophylaxis in hemophilia A/B without inhibitors: Results from the phase 3 BASIS trial. Blood, 146(14), 1654–1663. https://doi.org/10.1182/blood-2024027468
National Bleeding Disorders Foundation. (2021). Sanofi revises fitusiran dosing regimen to mitigate risk of vascular thrombosis. https://www.bleeding.org/news/sanofi-revises-fitusiran-dosing-regimen-to-mitigate-risk-of-vascular-thrombosis
National Institute of Diabetes and Digestive and Kidney Diseases. (2025). Fitusiran. In LiverTox: Clinical and research information on drug-induced liver injury. National Institutes of Health. https://www.ncbi.nlm.nih.gov/books/NBK617442/
Négrier, C., Mahlangu, J., Lehle, M., Chowdary, P., Catalani, O., Bernardi, R. J., Jiménez-Yuste, V., Beckermann, B. M., Schmitt, C., Ventriglia, G., Windyga, J., d’Oiron, R., Moorehead, P., Koparkar, S., Teodoro, V., Shapiro, A. D., Oldenburg, J., & Hermans, C. (2023). Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): A multicentre, open-label, single-arm, phase 3 study. The Lancet. Haematology, 10(3), e168–e177. https://doi.org/10.1016/S2352-3026(22)00377-5
Novo Nordisk Inc. (2025). Concizumab-mtci (Alhemo) package insert. https://www.novo-pi.com/alhemo.pdf
Pfizer Inc. (2024). Marstacimab-hncq (Hympavzi) package insert. https://labeling.pfizer.com/ShowLabeling.aspx?id=20916
Pipe, S. W., Lissitchkov, T., Georgiev, P., Mangles, S., Hegemann, I., Trinchero, A., Chowdary, P., Forbes, A., Feng, L., Menapace, L. A., Kichou, S., Andersson, S., Demissie, M., & Ragni, M. V. (2025). Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B. Blood Advances, 9(5), 1147–1158. https://doi.org/10.1182/bloodadvances.2024013900
Sanofi. (2025a). Fitusiran (Qfitlia) package insert. https://products.sanofi.us/qfitlia/qfitlia.pdf
Sanofi. (2025b). Interactive dosing tool for Qfitlia™ (fitusiran). https://pro.campus.sanofi/us/products/qfitlia/dosing-tool
Srivastava, A., Rangarajan, S., Kavakli, K., Klamroth, R., Kenet, G., Khoo, L., You, C. W., Xu, W., Malan, N., Frenzel, L., Bagot, C. N., Stasyshyn, O., Chang, C. Y., Poloskey, S., Qiu, Z., Andersson, S., Mei, B., & Pipe, S. W. (2023). Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): A multicentre, open-label, randomised, phase 3 trial. The Lancet Haematology, 10(5), e322–e332. https://doi.org/10.1016/S2352-3026(23)00037-6
Srivastava, A., Santagostino, E., Dougall, A., Kitchen, S., Sutherland, M., Pipe, S. W., Carcao, M., Mahlangu, J., Ragni, M. V., Windyga, J., Llinás, A., Goddard, N. J., Mohan, R., Poonnoose, P. M., Feldman, B. M., Lewis, S. Z., van den Berg, H. M., Pierce, G. F., & WFH Guidelines for the Management of Hemophilia panelists and co-authors (2020). WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 26(Suppl 6), 1–158. https://doi.org/10.1111/hae.14046
Thornburg, C. D., & Duncan, N. A. (2017). Treatment adherence in hemophilia. Patient Preference and Adherence, 11, 1677–1686. https://doi.org/10.2147/PPA.S139851
U.S. Food and Drug Administration. (2025). FDA approves novel treatment for hemophilia A or B, with or without factor inhibitors. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitor
Wang, S., Kattula, S., Ismail, A., Leksa, N., van der Flier, A., & Salas, J. (2020). Reducing antithrombin in plasma to levels observed in fitusiran-treated patients does not interfere with coagulation assays. Blood, 136(Supplement 1), 10. https://doi.org/10.1182/blood-2020-142724
Weyand, A. C., Malec, L., & Pipe, S. W. (2024). Advancements in haemophilia A and health equity: Is it time to redefine severity? The Lancet Haematology, 11(2), e90–e92. https://doi.org/10.1016/S2352-3026(23)00270-3
Young, G., Ali, S., Kaddi, C., Fetita, L.-S., Chhabra, E. S., Demissie, M., & Chou, S.-C. (2025a). Evaluating the safety and tolerability of switching from emicizumab to fitusiran prophylaxis in adult males with severe hemophilia A, with or without inhibitors: SWITCH study, a trial in progress. Blood, 146(Supplement 1), 3076. https://doi.org/10.1182/blood-2025-3076
Young, G., Kavakli, K., Klamroth, R., Matsushita, T., Peyvandi, F., Pipe, S. W., Rangarajan, S., Shen, M. C., Srivastava, A., Sun, J., Tran, H., You, C. W., Zülfikar, B., Menapace, L. A., Zhang, C., Shen, Y., Puurunen, M., Demissie, M., & Kenet, G. (2025b). Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: The ATLAS-OLE study. Blood, 145(25), 2966–2977. https://doi.org/10.1182/blood-2024027008
Young, G., Srivastava, A., Kavakli, K., Ross, C., Sathar, J., You, C. W., Tran, H., Sun, J., Wu, R., Poloskey, S., Qiu, Z., Kichou, S., Andersson, S., Mei, B., & Rangarajan, S. (2023). Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): A multicentre, open-label, randomised phase 3 trial. The Lancet, 401(10386), 1427–1437. https://doi.org/10.1016/S0140-6736(23)00284-2
Zaheer, S., Marquez Casas, E., & Young, G. (2025). In vitro comparison of eptacog beta and eptacog alfa with antithrombin lowering (simulated fitusiran) using thrombin generation assay. Blood, 146(Supplement 1), 1295. https://doi.org/10.1182/blood-2025-1295
